6120 RESULTS
CONFERENCE COVERAGE 2015-11-24 Conference Coverage The 8th Clinical Trials Conference on Alzheimer’s Disease, held November 5-7 in Barcelona, Spain, displayed the potential pitfalls of each of the many decisions that go into designing trials in early, pre-dementia AD. Amid a broad sens
CONFERENCE COVERAGE 2015-11-24 Conference Coverage As more drugs are entering the trials pipeline in ever-earlier-stage patients, the question of how to measure success is coming to the fore. The conventional model of measuring efficacy with dual cognitive and clinical scales such as A
CONFERENCE COVERAGE 2015-11-25 Conference Coverage Besides news on the most closely watched anti-amyloid drugs, the 8th Clinical Trials on Alzheimer’s Disease (CTAD) conference, held in Barcelona, Spain, November 5-7, featured a parade of lesser-known investigational therapies. Spannin
CONFERENCE COVERAGE 2015-11-25 Conference Coverage More candidate therapies have landed on the scrap heap of Alzheimer’s clinical trials, freeing up sites, investigators, and participants to try something else. At the 8th Clinical Trials on Alzheimer’s Disease conference, held November
CONFERENCE COVERAGE 2015-11-25 Conference Coverage The 8th Clinical Trials on Alzheimer’s Disease conference, held November 5-7 in Barcelona, Spain, featured results on at least four clinical trial debutants, i.e., Phase 1 entries. One evoked Queen Marie Antoinette’s acerbic observatio
CONFERENCE COVERAGE 2015-11-27 Conference Coverage It has become a mantra in the Alzheimer’s field that staying active—physically, cognitively, and socially—can protect the brain against decline. But can this be turned into a viable intervention? At the 8th Clinical Trials in Alzheimer
CONFERENCE COVERAGE 2015-11-26 Conference Coverage Geneticists have all but exhausted the genome-wide association approach to finding genetic variants that influence AD risk. Massive meta-analyses of more than 50,000 cases and controls have brought the total number of AD risk genes to
CONFERENCE COVERAGE 2015-11-27 Conference Coverage Despite early disappointments, drug developers have bought into immunotherapy for Alzheimer’s disease, banking on a handful of antibodies and active vaccines currently in Phase 2/3 trials and others in Phase 1. As evident from this yea
RESEARCH NEWS 2015-12-04 Research News Two new mouse models for amyotrophic lateral sclerosis and frontotemporal dementia display classic pathological signs of the C9ORF72 repeats they carry—but no sign of neurodegeneration. The models, generated by the groups of Robert Baloh at
RESEARCH NEWS 2015-12-04 Research News BRCA1, a DNA repair protein best known for its ties to breast cancer, appears to matter for Alzheimer’s disease as well. Scientists led by Lennart Mucke, Gladstone Institute of Neurological Disease, San Francisco, California, found that peop
RESEARCH NEWS 2015-12-10 Research News Longitudinal biomarker studies of Alzheimer’s disease have greatly advanced researchers’ understanding of disease progression. Now another such initiative seeks to further clarify the biological changes in early disease. The National Institu
CONFERENCE COVERAGE 2015-12-19 Conference Coverage More than 800 researchers, clinicians, and patients with ALS gathered in balmy Orlando, Florida, on December 11-13, for the 26th International Symposium on ALS/MND. Attendees felt a sense of urgency, but also hope—urgency because “time
CONFERENCE COVERAGE 2015-12-23 Conference Coverage For all the brain-imaging research scientists in North America and Europe have been doing on dementia with Lewy bodies (DLB) over the past decade, could it be said they were a little slow to catch on to an option that plainly does the
CONFERENCE COVERAGE 2015-12-23 Conference Coverage People with ALS now have more options to deal with a distressing set of symptoms called bulbar signs. These include difficulties with speech, swallowing, and salivation that result from neurodegeneration of the bulb-shaped brainstem. T
RESEARCH NEWS 2015-12-23 Research News Researchers know that repeated blows to the head can precipitate a neurodegenerative tauopathy called chronic traumatic encephalopathy (CTE). Marked by memory loss, movement problems, and changes in mood such as depression and anger, this di
